Animal models for drug discovery in dystonia

Bibliography

• Fahn S. The varied clinical expressions of dystonia. Neurol Clin 1984;2:541-54
   PubMed Web of Science ®Google Scholar
• Fahn S. Concept and classification of dystonia. Adv Neurol 1988;50:1-8
   PubMedGoogle Scholar
• Bressman SB. Dystonia: phenotypes and genotypes. Rev Neurol 2003;159:849-56
   PubMed Web of Science ®Google Scholar
• Nemeth AH. The genetics of primary dystonias and related disorders. Brain 2002;125:695-721
   PubMed Web of Science ®Google Scholar
• Decarvalho Aguiar PM, Ozelius LJ. Classification and genetics of dystonia. Lancet Neurol 2002;1:316-25
   PubMed Web of Science ®Google Scholar
• Defazio G. Epidemiology of primary and secondary dystonia. In: Handbook of Dystonia. Stacey ME (Ed.), New York, USA: Informa Healthcare; 2007. p. 11-20
   Google Scholar
• Tolosa E, Compta Y. Dystonia in Parkinson's disease. J Neurol 2006;253(Suppl 7):7-13
   Google Scholar
• Jankovic J, Tintner R. Dystonia and parkinsonism. Parkinsonism Rel Disord 2001;8:109-21
   PubMed Web of Science ®Google Scholar
• Sanger TD, Delgado MR, Gaebler-Spira D, et al. Classification and definition of disorders causing hypertonia in childhood. Pediatrics 2003;111:89-97
   Google Scholar
• Kyllerman M, Bager B, Bensch J, et al. Dyskinetic cerebral palsy. I. Clinical categories, associated neurological abnormalities and incidences. Acta Pediatr Scand 1982;71:543-50
   PubMed Web of Science ®Google Scholar
• Albright AL, Barry MJ, Shafron DH, Ferson SS. Intrathecal baclofen for generalized dystonia. Dev Med Child Neurol 2001;43:652-7
   PubMed Web of Science ®Google Scholar
• Jankovic J. Treatment of dystonia. Lancet Neurol 2006;5:864-72
   PubMed Web of Science ®Google Scholar
• Albanese A, Barnes MP, Bhatia KP, et al. A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: repor of an EFNS/MDS-ES task force. Eur J Neurol 2006;13:433-44
   PubMedGoogle Scholar
• Greene P. Baclofen in the treatment of dystonia. Clin Neuropharmacol 1992;15:276-88
   PubMed Web of Science ®Google Scholar
• Walker RH, Danisi FO, Swope DM, et al. Intrathecal baclofen for dystonia: benefits and complications during six years of experience. Mov Disord 2000;15:1242-7
   PubMed Web of Science ®Google Scholar
• Arce CA. Selective denervation in cervical dystonia. In: Handbook of dystonia. Stacey MA (Ed.), New York, USA: Informa Healthcare; 2007. p. 381-92
   Google Scholar
• Marks WJJ. Brain surgery for dystonia. In: Handbook of Dystonia. Stacey MA (Ed.), New York, USA: Informa Healtcare; 2007. p. 393-406
   Google Scholar
• Jinnah HA, Hess EJ, Ledoux MS, et al. Rodent models for dystonia research: characteristics, evaluation, and utility. Mov Disord 2005;20:283-92
   PubMed Web of Science ®Google Scholar
• Ozelius LJ, Hewett JW, Page CE, et al. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat Genet 1997;17:408
   Google Scholar
• Hewett JW, Gonzalez-Agosti C, Slater D, et al. Mutant torsinA, responsible for early-onset torsion dystonia, forms membrane inclusions in cultured neural cells. Hum Mol Genet 2000;9:1403-13
   PubMed Web of Science ®Google Scholar
• Goodchild RE, Kim CE, Dauer WT. Loss of the dystonia-associated protein torsinA selectively disrupts the neuronal nuclear envelope. Neuron 2005;48:923-32
   PubMed Web of Science ®Google Scholar
• Shashidharan P, Sandu D, Potla U, et al. Transgenic mouse model of early-onset dyt1 dystonia. Hum Mol Genet 2005;14(1):125-33
   PubMed Web of Science ®Google Scholar
• Sharma N, Baxter MG, Petravicz J, et al. Impaired motor learning in mice expressing torsinA with the dyt1 dystonia mutation. J Neurosci 2005;25(22):5351-5
   PubMed Web of Science ®Google Scholar
• Grundmann M, Reischmann B, Vanhoutte G, et al. Overexpression of human wildtype torsinA and human deltaGAG torsinA in a transgenic mousemodel causes phenotypic abnormalities. Neurobiol Dis 2007;27:19-206
   PubMedGoogle Scholar
• Dang MT, Yokoi F, McNaught KS, et al. Generation and characterization of Dyt1 deltaGAG knock-in mouse as a model for early-onset dystonia. Exp Neurol 2005;196:452-63
   PubMed Web of Science ®Google Scholar
• Duchen LW. Dystonia musculorum – an inherited disease of the nervous system in the mouse. Adv Neurol 1976;14:353-65
   PubMed Web of Science ®Google Scholar
• Lorden JF, McKeon TW, Baker HJ, et al. Characterization of the rat mutant dystonic (dt): a new animal model of dystonia musculorum deformans. J Neurosci 1984;4:1925-32
   PubMed Web of Science ®Google Scholar
• Loscher W, Fisher JE, Schmidt D, et al. The sz mutant hamster: a genetic model of epilepsy or of paroxysmal dystonia? Mov Disord 1989;4:219-32
   PubMed Web of Science ®Google Scholar
• Richter A, Loscher W. Pathology of idiopathic dystonia: findings from genetic animal models. Prog Neurobiol 1998;54:633-77
   PubMed Web of Science ®Google Scholar
• Gernert M, Bennay M, Fedrowitz M, et al. Altered discharge pattern of basal ganglia output neurons in an animal model of idiopathic dystonia. J Neurosci 2002;22:7244-53
   PubMed Web of Science ®Google Scholar
• Fletcher CF, Lutz CM, O'Sullivan TN, et al. Absence epilepsy in tottering mutant mice is associated with calcium channel defects. Cell 1996;87:607-17
   PubMedGoogle Scholar
• Wakamori M, Yamazaki K, Matsunodaira H. Single tottering mutations responsible for the neuropathic phenotype of the P-type calcium channel. J Biol Chem 1998;52:34857-67
   PubMed Web of Science ®Google Scholar
• Campbell DB, Hess EJ. Cerebellar circuitry is activated during convulsive episodes in the tottering (tg/tg) mutant mouse. Neuroscience 1998;85:773-83
   PubMed Web of Science ®Google Scholar
• Campbell DB, North JB, Hess EJ. Tottering mouse motor dysfunction is abolished on the Purkinje cell degeneration (pcd) mutant background. Exp Neurol 1999;160:268-78
   PubMedGoogle Scholar
• Byl NN. Focal hand dystonia may result from aberrant neuroplasticity. Adv Neurol 1994;94:19-28
   Web of Science ®Google Scholar
• Mink JW, Thach WT. Basal ganglia motor control. III. Pallidal ablation: normal reaction time, muscle cocontraction, and slow movement. J Neurophysiol 1991;65:330-51
   PubMed Web of Science ®Google Scholar
• Burns LH, Pakzaban P, Deacon TW, et al. Selective putaminal excitotoxic lesions in non-human primates model the movement disorder of Huntington disease. Neuroscience 1995;64:1007-17
   PubMed Web of Science ®Google Scholar
• Foltz EL, Knopp LM, Ward AA. Experimental spasmodic torticollis. J Neurosurg 1959;16:55-67
   PubMed Web of Science ®Google Scholar
• Malouin F, Bedard PJ. Frontal torticollis (head tilt) induced by electrolytic lesion and kainic acid injection in monkeys and cats. Exp Neurol 1982;78:551-60
   PubMed Web of Science ®Google Scholar
• Klier EM, Wang H, Constantin AG, Crawford JD. Midbrain control of three-dimensional head orientation. Science 2002;295:1314-16
   PubMedGoogle Scholar
• Marsden CD, Obeso JA, Zarranz JJ. The anatomical basis of symptomatic dystonia. Brain 1985;108:463-83
   PubMed Web of Science ®Google Scholar
• Perlmutter JS, Tempel LW, Black KJ, et al. MPTP induces dystonia and parkinsonism. Clues to the pathophysiology of dystonia. Neurology 1997;49:1432-8
   PubMed Web of Science ®Google Scholar
• Tabbal SD, Mink JW, Antenor JAV, et al. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced acute transient dystonia in monkeys with low striatal dopamine. Neuroscience 2006;141:1281-7
   PubMedGoogle Scholar
• Boyce S, Clarke CE, Luguin R, et al. Induction of chorea and dystonia in Parkinsonian primates. Mov Disord 1990;5:3-7
   PubMed Web of Science ®Google Scholar
• Olanow CW, Good PF, Shinotoh H, et al. Manganese intoxication in the rhesus monkey: a clinical, imaging, pathologic, and biochemical study. Neurology 1996;46:492-8
   PubMed Web of Science ®Google Scholar
• Ghorayeb I, Fernagut PO, Stefanova N, et al. Dystonia is predictive of subsequent altered dopaminergic responsiveness in a chronic 1-methyl4-phenyl-1,2,3,6-tetrahydropyridine + 3-nitropropionic acid model of striatonigral degeneration in monkeys. Neurosci Lett 2002;335:34-8
   PubMedGoogle Scholar
• Brouillet E, Hantraye P, Ferrante RJ, et al. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci USA 1995;92:7105-9
   PubMed Web of Science ®Google Scholar
• Segalat L. Invertebrate animal models of diseases as screening tools in drug discovery. ACS Chem Biol 2007;2:231-6
   PubMed Web of Science ®Google Scholar
• Caldwell GA, Cao S, Izevbaye I, Caldwell KA. Use of C. elegans to model human movement disorders. In: Animal Models of Movement Disorders. LeDoux MS (Ed.), Burlington, USA: Elsevier; 2005. p. 111-26
   Google Scholar
• Betarbet R, Sherer TB, Greenamyre JT. Animal models of Parkinson's disease. Bioessays 2002;24:308-18
   PubMed Web of Science ®Google Scholar
• Hirsch EC, Hoglinger G, Rousselet E, et al. Animal models of Parkinson's disease in rodents induced by toxins: an update. Neural Transm Suppl 2003;65:89-100
   PubMed Web of Science ®Google Scholar
• Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiology of Parkinson's disease. Ann Rev Neurosci 2005;28:57-87
   PubMed Web of Science ®Google Scholar
• Cookson MR. The biochemistry of Parkinson's disease. Annu Rev Biochem 2005;74:29-52
   PubMed Web of Science ®Google Scholar
• Benatar M. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis 2007;26:1-13
   PubMedGoogle Scholar
• Friese MA, Montalban X, Willcox N, et al. The value of animal models for drug development in multiple sclerosis. Brain 2006;129:1940-52
   PubMed Web of Science ®Google Scholar
• Cheng YD, Al-Khoury L, Zivin JA. Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRx 2004;1:36-45
   PubMedGoogle Scholar
• Gladstone DJ, Black SE, Hakim AM. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 2002;33:2123-36
   PubMed Web of Science ®Google Scholar
• Green AR, Odergren T, Ashwood T. Animal models of stroke: do they have value for discovering neuroprotective agents? Trends Pharmacol Sci 2003;24:402-8
   PubMed Web of Science ®Google Scholar
• O'Collins VE, MacLeod MR, Donnan GA, et al. 1,026 experimental treatments in acute stroke. Ann Neurol 2006;59:467-77
   PubMed Web of Science ®Google Scholar
• Rogawski MA. Molecular targest versus modesl for new antiepileptic drug discovery. Epilepsy Res 2006;68:22-8
   PubMed Web of Science ®Google Scholar
• Gonzalez-Alegre P, Bode N, Davidson BL, Paulson HL. Silencing primary dystonia: lentiviral-mediated RNA interference therapy for DYT1 dystonia. J Neurosci 2005;25:10502-9
   PubMed Web of Science ®Google Scholar
• Caldwell GA, Cao S, Sexton EG, et al. Suppression of polyglutamine-induced protein aggregation in Caenorhabditis elegans by torsin proteins. Hum Mol Genet 2003;12:307-19
   PubMed Web of Science ®Google Scholar
• Richter A, Sander SE, Rundfeldt C. Antidystonic effects of Kv7 (KCNA) channel openers in the dt sz mutant, an animal model of primary paroxsymal dystonia. Br J Pharmacol 2006;149:747-53
   PubMedGoogle Scholar
• Hess EJ, Jinnah HA. Mouse models of dystonia. In: Animal Models of Movement Disorders. Le Doux MS (Ed.), San Diego, USA: Elsevier; 2005. p. 265-77
   Google Scholar
• Giffin NJ, Benton S, Goadsby PJ. Benign paroxysmal torticollis of infancy: four new cases and linkage to CACNA1A mutation. Dev Med Child Neurol 2002;44:490-3
   PubMed Web of Science ®Google Scholar
• Spacey SD, Materek LA, Szczygielski BI, Bird TD. Two novel CACNA1A gene mutations associated with episodic ataxia type 2 and interictal dystonia. Arch Neurol 2005;62:314-16
   PubMed Web of Science ®Google Scholar
• Jinnah HA, Sepkuty JP, Ho T, et al. Calcium channel agonists and dystonia in the mouse. Mov Disord 2000;15:542-51
   PubMed Web of Science ®Google Scholar
• Street VA, Bosma MM, Demas VP, et al. The type 1 inositol triphosphate receptor gene is altered in the opisthotonus mouse. J Neurosci 1997;17:635-47
   PubMed Web of Science ®Google Scholar
• Matsumoto M, Nakagawa T, Inoue T, et al. Ataxia and epileptic seizures in mice lacking type 1 inositol 1,4,5-triphosphate receptor. Nature 1996;379:168-71
   PubMedGoogle Scholar
• Campbell DB, Hess EJ. L-type calcium channels contribute to the tottering mouse dystonic episodes. Mol Pharmacol 1999;55:23-31
   PubMed Web of Science ®Google Scholar
• Khan Z, Carey J, Park HJ, et al. Abnormal motor behavior and vestibular dysfunction in the stargazer mouse mutant. Neuroscience 2004;127:785-96
   PubMedGoogle Scholar
• Khan Z, Jinnah HA. Paroxysmal dyskinesias in the lethargic mouse mutant. J Neurosci 2002;22:8193-200
   PubMed Web of Science ®Google Scholar
• Richter A, Loscher W. Antidystonic effects of L-type Ca2+ channel antagonists in a hamster model of idiopathic dystonia. Eur J Pharmacol 1996;300:197-202
   PubMedGoogle Scholar
• Cates M, Lusk K, Wells BG. Are calcium-channel blockers effective in the treatment of tardive dyskinesia? Ann Pharmacother 1993;27:191-6
   PubMed Web of Science ®Google Scholar
• Perlmutter JS, Mink JW. Dysfunction of dopaminergic pathways in dystonia. Adv Neurol 2004;94:163-70
   PubMedGoogle Scholar
• Hallett M. Pathophysiology of dystonia. J Neural Transm Suppl 2006;70:485-8
   PubMed Web of Science ®Google Scholar
• Quartarone A, Siebner HR, Rothwell JC. Task-specific hand dystonia: can too much plasticity be bad for you? Trends Neurosci 2006;29:192-9
   PubMed Web of Science ®Google Scholar
• Eriksen JL, Wszolek Z, Petrucelli L. Molecular pathogenesis of Parkinson disease. Arch Neurol 2005;62:353-7
   PubMed Web of Science ®Google Scholar
• Balcioglu A, Kim MO, Sharma N, et al. Dopamine release is impaired in a mouse model of DYT1 dystonia. J Neurochem 2007;102:783-8
   PubMed Web of Science ®Google Scholar